title: Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
abstract: It has not been elucidated whether the clinical efficacy of oral fluoropyrimidines for adjuvant chemotherapy of colorectal cancer varies with tumor biological characteristics.
  
  
  
  A multicenter randomized trial was performed comparing oral tegafur/gimeracil/oteracil (S-1) and uracil-tegafur/ leucovorin (UFT/LV) as adjuvant therapy for stage III colorectal cancer. Postoperative survival was compared based on the 5-FU-related mRNA levels in cancer tissues.
  
  
  
  Among patients with tumor expressing dihydropyrimidine dehydrogenase (DPD) mRNA within the 66.7th percentile (lower 2/3) of all cases, overall survival (OS) was significantly better in the S-1 than in the UFT/LV group. In the S-1 group, patients with low DPD-expressing tumors had significantly better OS than those with highly expressing tumors. Patients with low thymidine synthase (TS)-expressing tumors had significantly better OS than those with highly expressing tumors.
  
  
  
  The efficacy of oral fluoropyrimidines as adjuvant chemotherapy for colorectal cancer may be influenced by the level of 5-FU-related mRNA in cancer tissues.
authors: Department of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan k-koda@med.teikyo-u.ac.jp.
authors: Keiji
authors: K
authors: Koda
authors: Department of Academic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
authors: Hideaki
authors: H
authors: Miyauchi
authors: Department of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan.
authors: Chihiro
authors: C
authors: Kosugi
authors: Department of Surgery, Kimitsu Chuo Hospital, Chiba, Japan.
authors: Takashi
authors: T
authors: Kaiho
authors: Department of Surgery, Chiba Prefectural Cancer Center, Chiba, Japan.
authors: Nobuhiro
authors: N
authors: Takiguchi
authors: Department of Surgery, Chiba Prefectural Sawara Hospital, Chiba, Japan.
authors: Susumu
authors: S
authors: Kobayashi
authors: Department of Surgery, Funabashi Municipal Medical Center, Chiba, Japan.
authors: Takashi
authors: T
authors: Maruyama
authors: Department of Academic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
authors: Hisahiro
authors: H
authors: Matsubara
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000235:genetics; D004338:Drug Combinations; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009962:Orotate Phosphoribosyltransferase / Q000235:genetics; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000378:metabolism; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*; D013762:Tetrahydrofolate Dehydrogenase / Q000235:genetics; D013939:Thymidine Phosphorylase / Q000235:genetics; D013940:Thymidylate Synthase / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D012333:RNA, Messenger; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D042943:Dihydrouracil Dehydrogenase (NADP); D013762:Tetrahydrofolate Dehydrogenase; D013940:Thymidylate Synthase; D009962:Orotate Phosphoribosyltransferase; D013939:Thymidine Phosphorylase; D002955:Leucovorin; D005472:Fluorouracil
keywords: 5-FU-metabolizing enzyme; Colon cancer; S-1; adjuvant therapy; dihydropyrimidine dehydrogenase; leucovorin; rectal cancer; thymidine synthase; uracil-tegafur